111 related articles for article (PubMed ID: 27479828)
21. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
[TBL] [Abstract][Full Text] [Related]
22. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
[TBL] [Abstract][Full Text] [Related]
23. TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.
Eckhoff L; Nielsen M; Moeller S; Knoop A
Acta Oncol; 2011 Oct; 50(7):1075-82. PubMed ID: 21824038
[TBL] [Abstract][Full Text] [Related]
24. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.
Vogel CL; Wojtukiewicz MZ; Carroll RR; Tjulandin SA; Barajas-Figueroa LJ; Wiens BL; Neumann TA; Schwartzberg LS
J Clin Oncol; 2005 Feb; 23(6):1178-84. PubMed ID: 15718314
[TBL] [Abstract][Full Text] [Related]
25. [Clinical burden caused by hospitalization for febrile neutropenia in France in 2010-2011: An analysis of the PMSI database].
Freyer G; Scotte F; Borget I; Bruyas A; Vainchtock A; Chouaid C
Bull Cancer; 2016 Jun; 103(6):552-60. PubMed ID: 27233367
[TBL] [Abstract][Full Text] [Related]
26. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Chan S
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
[TBL] [Abstract][Full Text] [Related]
27. Healthcare utilisation in patients with breast cancer or non-Hodgkin lymphoma who experienced febrile neutropenia in the Netherlands: a retrospective matched control study using the PHARMO database.
Issa DE; Gelderblom H; Lugtenburg PJ; van Herk-Sukel MP; Houweling LM; De La Orden M; van der Werf-Langenberg ME; Nortier JW; de Jong FA
Eur J Cancer Care (Engl); 2015 Mar; 24(2):232-41. PubMed ID: 24528512
[TBL] [Abstract][Full Text] [Related]
28. Impact of time to antibiotic on hospital stay, intensive care unit admission, and mortality in febrile neutropenia.
Daniels LM; Durani U; Barreto JN; O'Horo JC; Siddiqui MA; Park JG; Tosh PK
Support Care Cancer; 2019 Nov; 27(11):4171-4177. PubMed ID: 30805726
[TBL] [Abstract][Full Text] [Related]
29. Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer.
Rulach RJ; McKay S; Neilson S; White L; Wallace J; Carruthers R; Lamb C; Cascales A; Marashi H; Glen H; Venugopal B; Sadoyze A; Sidek N; Russell JM; Alhasso A; Dodds D; Laskey J; Jones RJ; MacLeod N
BJU Int; 2018 Feb; 121(2):268-274. PubMed ID: 28940952
[TBL] [Abstract][Full Text] [Related]
30. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522
[TBL] [Abstract][Full Text] [Related]
31. Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors.
Pfeil AM; Vulsteke C; Paridaens R; Dieudonné AS; Pettengell R; Hatse S; Neven P; Lambrechts D; Szucs TD; Schwenkglenks M; Wildiers H
BMC Cancer; 2014 Mar; 14():201. PubMed ID: 24641830
[TBL] [Abstract][Full Text] [Related]
32. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
[TBL] [Abstract][Full Text] [Related]
33. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia.
Hansson EK; Friberg LE
Cancer Chemother Pharmacol; 2012 Apr; 69(4):881-90. PubMed ID: 22057837
[TBL] [Abstract][Full Text] [Related]
34. Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study.
Freyer G; Hennebert P; Awada A; Gil T; Kerger J; Selleslags J; Brassinne C; Piccart M; de Valeriola D
Clin Cancer Res; 2002 Jan; 8(1):95-102. PubMed ID: 11801544
[TBL] [Abstract][Full Text] [Related]
35. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.
Mackey JR; Ramos-Vazquez M; Lipatov O; McCarthy N; Krasnozhon D; Semiglazov V; Manikhas A; Gelmon KA; Konecny GE; Webster M; Hegg R; Verma S; Gorbunova V; Abi Gerges D; Thireau F; Fung H; Simms L; Buyse M; Ibrahim A; Martin M
J Clin Oncol; 2015 Jan; 33(2):141-8. PubMed ID: 25185099
[TBL] [Abstract][Full Text] [Related]
36. Optimal use of docetaxel (Taxotere): maximizing its potential.
Burris HA
Anticancer Drugs; 1996 Aug; 7 Suppl 2():25-8. PubMed ID: 8862707
[TBL] [Abstract][Full Text] [Related]
37. An open-label multicenter safety, tolerability, and efficacy study of recombinant granulocyte colony-stimulating factor in the prevention of neutropenic complications in breast cancer patients.
Sveikata A; Liutkauskienė S; Juozaitytė E; Characiejus D; Tamošaitytė L; Šeštakauskas K
Medicina (Kaunas); 2011; 47(8):428-33. PubMed ID: 22123557
[TBL] [Abstract][Full Text] [Related]
38. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
[TBL] [Abstract][Full Text] [Related]
39. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
Piccart MJ; Klijn J; Paridaens R; Nooij M; Mauriac L; Coleman R; Bontenbal M; Awada A; Selleslags J; Van Vreckem A; Van Glabbeke M
J Clin Oncol; 1997 Sep; 15(9):3149-55. PubMed ID: 9294478
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.
Lee JL; Ryu MH; Chang HM; Kim TW; Yook JH; Oh ST; Kim BS; Kim M; Chun YJ; Lee JS; Kang YK
Cancer Chemother Pharmacol; 2008 Apr; 61(4):631-7. PubMed ID: 17520252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
